Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Hee Ryeong | - |
dc.contributor.author | Song, Moo Kon | - |
dc.contributor.author | Chung, Joo Seop | - |
dc.contributor.author | Yang, Deok Hwan | - |
dc.contributor.author | Lee, Jeong Ok | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Cho, Su Hee | - |
dc.contributor.author | Kim, Seong Jang | - |
dc.contributor.author | Shin, Dong Hoon | - |
dc.contributor.author | Park, Young Joo | - |
dc.contributor.author | Kang, Jin-Suk | - |
dc.contributor.author | Lee, Jeong Eun | - |
dc.contributor.author | Lee, Moon Won | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.date.available | 2020-02-28T09:42:06Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-06 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10469 | - |
dc.description.abstract | Background Few clinical studies have clarified the prognostic factors that affect clinical outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after immunochemotherapy. Methods A total of 158 patients with relapsed or refractory DLBCL were enrolled. All patients underwent positron emission tomography/computed tomography (PET/CT) before and after salvage therapy. All enrolled patients previously received the ifosfamide, carboplatin, and etoposide regimen. Clinical outcomes were compared according to several factors (age >= 65 years, low age-adjusted International Prognostic Index [aa-IPI], maximum standardized uptake value [SUVmax] < 6.0 on PET/CT, time to relapse >= 12 months, complete response after salvage therapy). A low aa-IPI, SUVmax < 6.0, and time to relapse >= 12 months were independent prognostic factors for survival. Results In univariate analysis and multivariate analysis, SUVmax below 6.0 (P < 0.001 for progression-free survival (PFS), P < 0.001 for overall survival (OS)) and low aa-IPI (P < 0.001 for PFS, P < 0.001 for OS) were independent prognostic factors associated with favorable outcome. Conclusion The aa-IPI and initial SUVmax were powerful prognostic factors in patients with relapsed or refractory DLBCL. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC HEMATOLOGY | - |
dc.relation.isPartOf | BLOOD RESEARCH | - |
dc.title | Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000433694600008 | - |
dc.identifier.doi | 10.5045/br.2015.50.2.97 | - |
dc.identifier.bibliographicCitation | BLOOD RESEARCH, v.50, no.2, pp.97 - 102 | - |
dc.identifier.kciid | ART001999169 | - |
dc.identifier.scopusid | 2-s2.0-84932650495 | - |
dc.citation.endPage | 102 | - |
dc.citation.startPage | 97 | - |
dc.citation.title | BLOOD RESEARCH | - |
dc.citation.volume | 50 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Hong, Junshik | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Positron emission tomography | - |
dc.subject.keywordAuthor | SUVmax | - |
dc.subject.keywordAuthor | aa-IPI | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.